Jan Kral, MD, PhD, MSc, MBA
@kraljan.bsky.social
Doctor at Charles University and Motol University Hospital, Prague. Ph.D. in colorectal cance. Researcher in obesity, AI, and 3D printing. ESGE Social Media Group. Passionate about GI health and innovation.
🌟Vedolizumab & Ustekinumab: Safe for IBD Moms? 🌟
📊 Study: EPI-MERES registry (2014–2021).
🧪 Results:
✅ No extra risks vs. anti-TNFs.
⚠️ Ustekinumab: Slightly higher risk of small-for-gestational-age births.
💡 Conclusion: Reassuring safety, but more research needed!
📊 Study: EPI-MERES registry (2014–2021).
🧪 Results:
✅ No extra risks vs. anti-TNFs.
⚠️ Ustekinumab: Slightly higher risk of small-for-gestational-age births.
💡 Conclusion: Reassuring safety, but more research needed!
January 5, 2025 at 7:08 AM
🌟Vedolizumab & Ustekinumab: Safe for IBD Moms? 🌟
📊 Study: EPI-MERES registry (2014–2021).
🧪 Results:
✅ No extra risks vs. anti-TNFs.
⚠️ Ustekinumab: Slightly higher risk of small-for-gestational-age births.
💡 Conclusion: Reassuring safety, but more research needed!
📊 Study: EPI-MERES registry (2014–2021).
🧪 Results:
✅ No extra risks vs. anti-TNFs.
⚠️ Ustekinumab: Slightly higher risk of small-for-gestational-age births.
💡 Conclusion: Reassuring safety, but more research needed!
🔬🚀 #CrohnsDisease News‼️
🔗📘 tinyurl.com/ydwentvd
✅The REPREVIO trial
Early vedolizumab after ileocolonic surgery drastically cuts severe #Crohns recurrence (23.3% vs. 62.2%) and boosts the chance of lower Rutgeerts scores (77.8%)! 💪
✨ Fewer flares, better outcomes‼️
🔗📘 tinyurl.com/ydwentvd
✅The REPREVIO trial
Early vedolizumab after ileocolonic surgery drastically cuts severe #Crohns recurrence (23.3% vs. 62.2%) and boosts the chance of lower Rutgeerts scores (77.8%)! 💪
✨ Fewer flares, better outcomes‼️
December 15, 2024 at 8:34 AM
🔬🚀 #CrohnsDisease News‼️
🔗📘 tinyurl.com/ydwentvd
✅The REPREVIO trial
Early vedolizumab after ileocolonic surgery drastically cuts severe #Crohns recurrence (23.3% vs. 62.2%) and boosts the chance of lower Rutgeerts scores (77.8%)! 💪
✨ Fewer flares, better outcomes‼️
🔗📘 tinyurl.com/ydwentvd
✅The REPREVIO trial
Early vedolizumab after ileocolonic surgery drastically cuts severe #Crohns recurrence (23.3% vs. 62.2%) and boosts the chance of lower Rutgeerts scores (77.8%)! 💪
✨ Fewer flares, better outcomes‼️
🔥📚 Peer review is under pressure‼️
Can 🤖 AI be the solution?
📚🔗 tinyurl.com/44pt9m3f
A study dives into medical journals’ policies on AI-assisted peer review to uncover the trends. 🚀
Can 🤖 AI be the solution?
📚🔗 tinyurl.com/44pt9m3f
A study dives into medical journals’ policies on AI-assisted peer review to uncover the trends. 🚀
December 4, 2024 at 4:45 PM
🔥📚 Peer review is under pressure‼️
Can 🤖 AI be the solution?
📚🔗 tinyurl.com/44pt9m3f
A study dives into medical journals’ policies on AI-assisted peer review to uncover the trends. 🚀
Can 🤖 AI be the solution?
📚🔗 tinyurl.com/44pt9m3f
A study dives into medical journals’ policies on AI-assisted peer review to uncover the trends. 🚀
🚀 First Virtual Reality in Endoscopy Training! 🎮🩺
A big 🙏 you to Boston Scientific, University Hospital Motol, 2nd Faculty of Medicine, Charles University, and 3NDO for their incredible support! 🙌👏
Pushing the boundaries of education and innovation in endoscopy! 🌍✨
A big 🙏 you to Boston Scientific, University Hospital Motol, 2nd Faculty of Medicine, Charles University, and 3NDO for their incredible support! 🙌👏
Pushing the boundaries of education and innovation in endoscopy! 🌍✨
December 1, 2024 at 5:06 PM
🚀 First Virtual Reality in Endoscopy Training! 🎮🩺
A big 🙏 you to Boston Scientific, University Hospital Motol, 2nd Faculty of Medicine, Charles University, and 3NDO for their incredible support! 🙌👏
Pushing the boundaries of education and innovation in endoscopy! 🌍✨
A big 🙏 you to Boston Scientific, University Hospital Motol, 2nd Faculty of Medicine, Charles University, and 3NDO for their incredible support! 🙌👏
Pushing the boundaries of education and innovation in endoscopy! 🌍✨
💠Results:
📊 Target population: MASH with fibrosis stages 2-3.
✅ Promise: First FDA-approved 💊 offering hope for noncirrhotic MASH.
💠Challenges:
🩺 Noninvasive tools to identify F2-F3 patients.
⛔ Excluding advanced fibrosis until more data is available.
📊 Target population: MASH with fibrosis stages 2-3.
✅ Promise: First FDA-approved 💊 offering hope for noncirrhotic MASH.
💠Challenges:
🩺 Noninvasive tools to identify F2-F3 patients.
⛔ Excluding advanced fibrosis until more data is available.
December 1, 2024 at 6:10 AM
💠Results:
📊 Target population: MASH with fibrosis stages 2-3.
✅ Promise: First FDA-approved 💊 offering hope for noncirrhotic MASH.
💠Challenges:
🩺 Noninvasive tools to identify F2-F3 patients.
⛔ Excluding advanced fibrosis until more data is available.
📊 Target population: MASH with fibrosis stages 2-3.
✅ Promise: First FDA-approved 💊 offering hope for noncirrhotic MASH.
💠Challenges:
🩺 Noninvasive tools to identify F2-F3 patients.
⛔ Excluding advanced fibrosis until more data is available.
🚨 New Expert Panel Recomm. Alert 🚨
🔗📗 tinyurl.com/3he6rybk
💡Expert panel shares practical tips on initiating & monitoring #Resmetirom for #MASH with moderate to advanced fibrosis.
@cugastrohep.bsky.social @amergastroassn.bsky.social @aga-cgh.bsky.social
🔗📗 tinyurl.com/3he6rybk
💡Expert panel shares practical tips on initiating & monitoring #Resmetirom for #MASH with moderate to advanced fibrosis.
@cugastrohep.bsky.social @amergastroassn.bsky.social @aga-cgh.bsky.social
December 1, 2024 at 6:10 AM
🚨 New Expert Panel Recomm. Alert 🚨
🔗📗 tinyurl.com/3he6rybk
💡Expert panel shares practical tips on initiating & monitoring #Resmetirom for #MASH with moderate to advanced fibrosis.
@cugastrohep.bsky.social @amergastroassn.bsky.social @aga-cgh.bsky.social
🔗📗 tinyurl.com/3he6rybk
💡Expert panel shares practical tips on initiating & monitoring #Resmetirom for #MASH with moderate to advanced fibrosis.
@cugastrohep.bsky.social @amergastroassn.bsky.social @aga-cgh.bsky.social
🧪 Combination therapy: TNF antagonists + immunomodulators > monotherapy.
🕒 Early escalation: Advanced therapies > step-up after 5-ASA failure.
🕒 Early escalation: Advanced therapies > step-up after 5-ASA failure.
November 30, 2024 at 12:33 PM
🧪 Combination therapy: TNF antagonists + immunomodulators > monotherapy.
🕒 Early escalation: Advanced therapies > step-up after 5-ASA failure.
🕒 Early escalation: Advanced therapies > step-up after 5-ASA failure.
✅ Top therapies: Infliximab, vedolizumab, upadacitinib, ozanimod, etrasimod, ustekinumab, risankizumab, and guselkumab.
👩⚕️ Advanced-naïve patients: Prefer higher-efficacy meds (e.g., infliximab) for remission.
🚫 Avoid thiopurine/methotrexate monotherapy for induction.
👩⚕️ Advanced-naïve patients: Prefer higher-efficacy meds (e.g., infliximab) for remission.
🚫 Avoid thiopurine/methotrexate monotherapy for induction.
November 30, 2024 at 12:33 PM
✅ Top therapies: Infliximab, vedolizumab, upadacitinib, ozanimod, etrasimod, ustekinumab, risankizumab, and guselkumab.
👩⚕️ Advanced-naïve patients: Prefer higher-efficacy meds (e.g., infliximab) for remission.
🚫 Avoid thiopurine/methotrexate monotherapy for induction.
👩⚕️ Advanced-naïve patients: Prefer higher-efficacy meds (e.g., infliximab) for remission.
🚫 Avoid thiopurine/methotrexate monotherapy for induction.
🚨 New AGA Guideline 🚨
🔗📗 tinyurl.com/mwc4ve42
💡An updated for the pharmacological management of moderate-to-severe #ulcerativecolitis.
A patient-centered, evidence-based guide to empower practitioners! 💊
@ibddoctor.bsky.social @ibd-afzali.bsky.social @bottomlineibd.bsky.social
🔗📗 tinyurl.com/mwc4ve42
💡An updated for the pharmacological management of moderate-to-severe #ulcerativecolitis.
A patient-centered, evidence-based guide to empower practitioners! 💊
@ibddoctor.bsky.social @ibd-afzali.bsky.social @bottomlineibd.bsky.social
November 30, 2024 at 12:33 PM
🚨 New AGA Guideline 🚨
🔗📗 tinyurl.com/mwc4ve42
💡An updated for the pharmacological management of moderate-to-severe #ulcerativecolitis.
A patient-centered, evidence-based guide to empower practitioners! 💊
@ibddoctor.bsky.social @ibd-afzali.bsky.social @bottomlineibd.bsky.social
🔗📗 tinyurl.com/mwc4ve42
💡An updated for the pharmacological management of moderate-to-severe #ulcerativecolitis.
A patient-centered, evidence-based guide to empower practitioners! 💊
@ibddoctor.bsky.social @ibd-afzali.bsky.social @bottomlineibd.bsky.social